P2.04-02 AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) + Durvalumab + Carboplatin as 1L Treatment of Advanced/mNSCLC.
| Autor: | Aggarwal, C., Cheema, P., Arrieta, O., Bonanno, L., Borghaei, H., Hu, Y., Kim, D.-W., de Castro Junior, G., Hepner, A., Deng, C., González del Riego, M., Kato, T. |
|---|---|
| Zdroj: | Journal of Thoracic Oncology; 2023 Supplement, Vol. 18 Issue 11, pS305-S306, 2p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|